cyrilzakka/clinical-trials huggingface dataset:
Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing

Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing (20 or 60mg/day) according how fast the patient can metabolize (eliminate) the drug. The individual elimination capacity is genetically controlled and therefore all patients will be genotyped prior to therapy.


Eligibility Criteria:
Inclusion Criteria:

* Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by routine endoscopy will be recruited in different clinical and ambulant centres of gastroenterology; written informed consent is obligatory
* Range of Age: 20-70
* BMI: 20-30

Exclusion Criteria:

* Patients who are allergic to proton-pump inhibitors or show incompatibility
* Patients who have lactase deficiency
* Patients who have severe chronic disease
* Patients who participated in another study during the last three months
* Patients who are pregnant
Pulse Steroid Injection in Refractory Rheumatoid Arthritis

Remission or low disease activity in active rheumatoid arthritis

Assessment of rheumatoid arthritis activity by Disease activity score DAS28, DAS28 Erythrocyte sedimentation rate (ESR), American college of rheumatology (ACR) 20, ACR 50, ACR 70 will be done at baseline and every month for 3 consecutive months for both groups.

Eligibility Criteria:
Inclusion Criteria:

* Refractory rheumatoid arthritis patients

Exclusion Criteria:

* Other connective tissue diseases
* Endocrine diseases such as DM and thyroid disorders
Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Patients diagnosed with Multifocal Motor Neuropathy were confirmed based on the European Federation of Neurological Societies/ Peripheral. Nerve Society Guideline. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, patients receive NPB-01 1g/kg every 3weeks and evaluate the Medical Research Council（MRC） score and the Guy's Neurological Disability Scale（GNDS） et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.


Eligibility Criteria:
Inclusion Criteria:

* 1. Patients who need high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） therapy.
* 2. Patients who continued treatment for MMN without addition or increase at 30 days before informed consent.
* 3. Patients who MRC score increased 1 stage in greater than or equal to 2 muscles and not decreased relative other muscles to before at after in high-dose intravenous immunoglobulin therapy.
* 4. Patients with greater than or equal to twenty years old at informed consent.

Exclusion Criteria:

* 1. Patients treated with Plasmapheresis at 3 months before informed consent.
* 2. Patients treated with Rituximab or Natalizumab at 6 months before informed consent.
* 3. Patients treated with Interferon-beta at 6 months before informed consent.
* 4. Patients treated with high-dose intravenous immunoglobulin（greater than or equal to 1g/kg） at 8 weeks before informed consent.
* 5. Patients treated with intravenous immunoglobulin at 3 weeks before informed consent.
* 6. Patients with history of shock or hypersensitivity for NPB-01.
* 7. Patients with IgA deficiency.
* 8. Patients with malignancy.
* 9. Patients with impaired liver function.
* 10. Patients with impaired renal function.
* 11. Patients with cerebro- or cardiovascular disorders.
* 12. Patients with high risk of thromboembolism.
* 13. Patients with hemolytic/hemorrhagic anemia.
* 14. Patients with decreased cardiac function.
* 15. Patients with decreased platelet.
A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation

The most effective treatment for atlantoaxial dislocation is surgical treatment, with the principle of achieving reduction, reconstruction, and fusion of the atlantoaxial joint. The surgical strategies mainly include simple anterior approach, simple posterior approach, and combined anterior posterior approach. The investigators have summarized 904 cases of atlantoaxial instability or dislocation from 1998 to 2010 and preliminarily published the diagnosis and treatment strategy tree of the Third Hospital of Beijing Medical University. This strategy is divided into four types based on the severity of atlantoaxial dislocation: unstable, reversible, difficult to recover, and skeletal, and enters different surgical treatment processes. With the increase in the number of cases, accumulation of experience, and technological improvements in the past decade, spinal surgery colleagues have updated their classification diagnosis, diagnosis and treatment processes, and surgical techniques for atlantoaxial instability or dislocation.

However, the selection of treatment strategies for atlantoaxial dislocation is mostly based on the surgeon's own experience, and there is a lack of standardized, large-scale, and high-level evidence-based medical research on the safety and effectiveness of current empirical strategies. Based on this, this study intends to adopt a multicenter, retrospective, and prospective study to construct a high-quality clinical cohort of atlantoaxial dislocation, update the classification and diagnosis and treatment strategies of atlantoaxial dislocation. And conduct long-term follow-up on patients to evaluate their safety and effectiveness, guide the surgical treatment of atlantoaxial dislocation, and thus form a recognized diagnostic and treatment standard for atlantoaxial dislocation.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with atlantoaxial dislocation and treated with surgery

Exclusion Criteria:

* Disagree to participate in this study.
Mechanisms of Nudges on Families' Decision-Making Process

As part of a larger study, participants are told to read 1 out of 4 anecdotes depicting an organ donation scenario where they are required to make a decision on behalf of their mother who has just suffered an accident. The participants are then surveyed on their attitudes towards organ donation.

As part of a larger study, participants are given 1 out of 4 possible vignettes which depicts an organ donation scenario involving their mother. The possible vignettes consist of a Control condition, a Framing condition, a Normative condition and a condition that includes all the nudges. Participants are then given surveys to gauge their views and attitudes towards organ donation as a whole, their trust towards medical institutions and the doctors, their perceived manipulation from the doctor and their views on the altruistic nature of organ donation.

Eligibility Criteria:
Inclusion Criteria:

* Above age 21
* Singapore Citizens and Permanent Residents

Exclusion Criteria:

* Below age 21
* Non-citizens
* Not able to make decisions for self
Intraoperative Findings and Complications in Bariatric Surgery

Retrospective study with patients submitted to bariatric surgery between 2013 and 2016 at a single Institution. The objective was to analyze the incidence and causes of unexpected intraoperative findings and complications, change in surgical plan, extra surgeries and procedure interruption. All operative information was collected prospectively and aimed to describe any of the previous situations. Secondarily, a morbidity analysis was performed, correlating intraoperative complications with postoperative complications and length of stay.


Eligibility Criteria:
Inclusion Criteria:

* Patient submitted to bariatric surgery
* All patients met the guidelines defined by the National Institutes of Health (NIH) consensus: BMI equal or greater to 40kg/m2 or BMI 35 - 40 kg/m2 with some comorbidity

Exclusion Criteria:

* Patients with incomplete surgery data sheet and those subject to another type of bariatric surgery
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections. The study is an observational study, meaning that we are not providing any intervention that does not involve usual standard of care. Our chief goal is to find evidence of fungal infection by using traditional, approved methods of diagnosis, but by applying these methods in the same way and frequency among all study participants. We will be looking especially for evidence of a fungal infection known as Aspergillus, which can causes a serious lung infection called invasive aspergillosis (IA).

COVID-19 is a disease caused by infection with the novel coronavirus SARS-COV2 which emerged in late 2019 in Wuhan, China (1). This illness is associated with viral prodromal symptoms, then subsequently fever, cough, and shortness of breath (1). In a subset of patients, lower respiratory tract infection associated with respiratory failure develops. Among these patients, progression to severe respiratory failure and ARDS requiring ventilator support has occurred in an alarming number of patients at rates that are many-fold higher than what is typically associated with seasonal influenza A or B (2). One of the most feared complications of post-influenza respiratory failure is the development of invasive pulmonary aspergillosis which may occur in as many as 15-20% of those requiring ventilator support (based on European data) (3-6). Among those developing IA following influenza A or B, mortality of 50% or greater is reported (3-6).

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 years or older at the time of enrollment
* SARS-COV2 positivity by PCR with respiratory failure requiring mechanical ventilation for at least 72 hours
* Prior therapy with antifungals, including prophylaxis, is NOT an exclusion.

Exclusion Criteria:

* Life expectancy of less than 72 hours as determined by the site investigator.
* Expected to be weaned from mechanical ventilation in next 24 hours
* Care received in any setting other than an intensive care unit (ICU) at the time of enrollment
Nicorandil Study to Reduce Cardiac Death After Percutaneous Coronary Intervention (PCI) in Hemodialysis Patients

Survival after invasive coronary revascularization is worse in patients with chronic kidney disease than in those without it. The investigators aimed to examine whether oral administration of nicorandil, a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener, could improve the survival of end-stage renal disease patients with coronary artery disease by inhibiting cardiac death after coronary revascularization.


Eligibility Criteria:
Inclusion Criteria:

* Hemodialysis patients with coronary artery disease who had undergone a successful first PCI with bare-metal stents between July 1, 2001 and December 31, 2003.

Exclusion Criteria:

* Subjects with moderate or worse cardiac valvular disease or old myocardial infarction at the point of first PCI.
Recurrent Laryngeal Nerve's Motor Function: Sometimes Motor Fibers May Also Be Located in The Posterior Branch

The investigators hypothesized that, sometimes the posterior branch of the recurrent laryngeal nerve may also have motor function. The investigators aimed to evaluate motor function of the branches in the branching recurrent laryngeal nerves in this study.

This study group consisted of consecutive patients, undergoing thyroid and parathyroid surgery with IONM. Both anterior and posterior branches of the recurrent laryngeal nerves were assessed separately by both electromyography endotracheal tube for adduction and finger palpation for detection of laryngeal twitch due to posterior cricoarytenoid abduction. The recurrent laryngeal nerves having motor function only in the anterior branches were defined as group 1, whereas the nerves having motor function both in the anterior and posterior branches were as group 2.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who underwent parathyroid/thyroid surgery with intraoperative neuromonitoring ,
2. Patients who had normal vocal cord functions preoperatively. -

Exclusion Criteria:

1. Preoperative recurrent laryngeal nerve palsy,
2. Intentional nerve transection because of cancer invasion,
3. Assessment failure of recurrent laryngeal nerve function due to the deficiency of the intraoperative neuromonitoring equipment,.
4. Parathyroidectomy operations that recurrent laryngeal nerves were not fully dissected.

   -
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

This 2-arm study evaluated the efficacy and safety of Fuzeon with an integrase inhibitor in an expanded access program plus an optimized background antiviral regimen (AVR) in HIV-1 infected patients naive to Fuzeon and an integrase inhibitor. In the first cohort phase of the study (Phase I), eligible patients received Fuzeon 90 mg subcutaneously (SC) twice daily until confirmation of response (min/max = 8/16 weeks). In Phase II, the randomised comparator phase of the study, responders were randomized to receive Fuzeon either 90 mg SC twice a day or 180 mg SC once a day for a further 16 weeks. Non-responders and virological failures were terminated from the study. The anticipated time on study treatment was 3-9 months, and the target sample size was 210 individuals.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>=18 years of age
* HIV-1 infection
* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive
* GSS \>= 3 ; nucleosides excluded

Exclusion Criteria:

* Adverse clinical or laboratory experience \>ACTG Grade 4
* Untreated infection, intercurrent illness, drug toxicity or other condition contraindicating an antiretroviral regimen
* Malignancy requiring chemotherapy or radiotherapy
Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment

In this case series study, the investigators are testing the hypothesis that sublingual sufentanil (Dsuvia) will improve postoperative pain management in the Post Anesthesia Care Unit (PACU) in ambulatory surgery patients taking Suboxone.


Eligibility Criteria:
Inclusion Criteria:

* Age range 18-100 years
* Currently taking Suboxone
* ASA (American Society of Anesthesiology) physical score 1-3
* Able to provide a signed informed consent
* General anesthesia (either endotracheal intubation or laryngeal mask airway) or MAC (monitored anesthesia care) without the use of regional anesthesia

Exclusion Criteria:

* Known allergic reactions to Dsuvia and its excipients
* Severe respiratory illness including exacerbation of asthma attack
* Significant intraoperative hemodynamic instability
* Use of Regional anesthesia techniques
Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years old.
* The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.
* Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.
* Patients had follow-up data before and after treatment for 1 month and at least 6 months.

Exclusion Criteria:

* Patients with other fundus diseases or refractive interstitial opacity.
* During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.
* Various reasons led to incomplete patient data.
Application of Linked Color Imaging（LCI） in Diagnosis of Early Gastric Cancer(EGC)

the purpose of this study is to evaluate application value of LCI in the diagnosis of early gastric cancer.

The detection rate of early gastric cancer is still very low in China. The investigators need a new and effective screening method to improve the detection rate. LCI (linked-color imaging)is a new model of laser endoscopy which can provide brighter image. LCI can provide clear image which can make red part redder and white part whiter, so suspicious lesion could be found easier. The study of this randomized controlled trial is to discuss effectiveness of LCI in the diagnosis of early gastric cancer and to find a new method to improve the detection rate of early gastric cancer in China.

Eligibility Criteria:
Inclusion Criteria:

1. High-risk group of gastric cancer: H. pylori infection; previously suffering from chronic atrophic gastritis, intestinal metaplasia, gastric ulcer, gastric polyps, residual stomach after surgery, hypertrophic gastritis, malignant anemia and other precancerous diseases of gastric cancer;
2. First degree relatives of patients with gastric cancer;
3. There are other high risk factors for gastric cancer (high salt, salted diet, smoking, heavy drinking, etc.).
4. Patients with early gastric cancer treated with endoscopic therapy (ESD, EMR).
5. The informed consent has been signed.

Exclusion Criteria:

1. The TNM classification of cancer is consistent with those diagnosed by T2 above.
2. Patients with abnormal blood coagulation function or taking anticoagulants can not biopsy.
3. There were contraindications for gastroscopy.
4. A patient without self judgement;
5. Those who did not sign informed consent.
6. Previous gastroscopy has found suspicious lesions requiring careful examination.
PRECEE2 Perinatal Research

The aim of this study is to analyze the relationship between complications and adverse pregnancy outcomes and exposure to environmental factors in women living in Franche-Comté who gave birth between 2011 and 2025 at Besancon University Hospital.


Eligibility Criteria:
Inclusion Criteria:

* Women who gave birth at the CHUB between 01/01/2011 and 12/31/2025
* who have not expressed any objection to the processing of their data.

Exclusion Criteria:

* Legal incapacity or limited legal capacity
* Subject is within the exclusion period of another study or is excluded from the "national volunteer file".
* Subject refusing the collection of his/her medical data.
The Belgian REAL (BE.REAL) Registry

This is an observational non-interventional study. The visit schedule is according to the routine clinical practice. Only data corresponding to study variables within the specified study period will be collected.

The study will recruit patients into one single cohort: Inclisiran in combination with other LLTs. The patients will receive Inclisiran therapy as per the approved label and Belgian reimbursement conditions.

The study aims to assess the effectiveness, safety and adherence for Inclisiran in combination with lipid-lowering therapy (LLT) under conditions of routine clinical practice. The Inclisiran cohort will include patients receiving Inclisiran therapy as per the approved label independently of background Standard of Care (SoC) therapy. This study will include both primary data collection and secondary use of data.

* Prospective data collection: Patients will be enrolled over a period of 6 months between 01-December-2022 and 31-May-2023 and will have a maximum follow-up of 39 months or 8 injection visits.
* Retrospective data collection: Retrospective data will also be captured for patients with a first prescription between 01-May-2022 and study start and will be followed up for a maximum of 39 months to assess for study outcomes. In this case, baseline data and data of the first injection visits will be retrieved by the physician and captured in the Clinical Report Form (CRF), followed by prospective data collection during the rest of the follow-up period.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who are 18 years or older.
2. Patients with Atherosclerotic Cardiovascular Disease (ASCVD) who are eligible for commercially available Leqvio, as defined by the reimbursement criteria:

   Patients with ASCVD documented by previous coronary heart disease (CHD), cerebrovascular disease or peripheral artery disease (PAD) and LDL-C ≥ 100mg/dL despite a treatment of min 6 weeks with max tolerated statin (unless intolerance or contra-indication) in combination with ezetimibe (unless intolerance or contra-indication).
3. Heterozygous Familial Hypercholesterolemia (HeFH) patients with documented ASCVD who are eligible for commercially available Leqvio.
4. Patients who provide written informed consent to participate in the study.

Exclusion Criteria:

1. Patients who have received Inclisiran previously.
2. Patients participating in a clinical trial with investigational product.
3. Heterozygous Familial Hypercholesterolemia patients without established Atherosclerotic Cardiovascular Disease.
Ultrasound TFP (Transversalis Fascia Plane) for Analgesia After Iliac Crest Bone Graft Harvest

Iliac crest bone graft harvest is associated with acute pain that can lead to chronic postoperative pain. Local anesthetic infiltration and regional anesthesia could be of interest to reduce opioid consumption during and after surgery, reduce hyperalgesia and the associated risk of chronic postoperative pain. In this surgery, local anesthetic infiltration of the iliac crest is associated with a pain reduction compare with placebo.

Some studies have shown the benefit of a TAP (transversus abdominal block) for postoperative analgesia after iliac crest bone graft harvest. The TFP block (transversalis fascia plane block) has been recently described. Considering the nerves trajectories, the TFP block is probably anatomically the most appropriate block for analgesia after iliac crest bone graft harvest.

The aim of this study is therefore to assess the benefit of an ultrasound TFP block for analgesia after iliac crest bone graft harvest compare with local anesthetic infiltration Design is prospective, randomized, double blind, controlled study


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Patients scheduled for iliac crest bone graft harvest during upper or lower limb surgery

Exclusion Criteria:

* Allergy to ropivacaine, propofol, paracetamol, remifentanil, morphine, cisatracurium, ketoprofene, nefopam
* Weight \< 50 kg
* Pregnancy
* Severe psychiatric disorder
* Paraplegia or tetraplegia
* Spinal anesthesia
* Contra indication to ketoprofene: age ≥ 75 years, renal insufficiency (creatinine clearance \< 50 ml/min), active gastric ulcer, past of asthma with NSAID
* Contra indication to nefopam: severe cardiac insufficiency, glaucoma, prostate hypertrophy, epilepsy
* Contra indication to paracetamol: severe hepatic insufficiency
* Severe respiratory insufficiency
* Abnormal hemostasis or anticoagulant treatment
* Chronic use of morphine